WillItSurvive
Medical technology and health companies · United States

Amwell

amwell.com ↗

Amwell runs a telehealth platform connecting patients, doctors, and hospitals via video and software.

Protection under test
Assessed 22 July 2026 · Evidence as of 22 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 22 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Target date for positive operating cash flow
The call

Amwell survives on contracted enterprise ties while its video layer gets commoditized by Zoom and its clinical workflow gets absorbed by Epic.

Amwell sells video visit software and patient scheduling to large health insurance companies and hospital systems. It is hard to replace because those customers have signed long contracts and depend on Amwell to connect thousands of doctors and patients every day. But Zoom has become the number one telehealth tool by market share and charges almost nothing, while Epic (the huge medical records software company) is now offering telehealth built right into its own system where doctors already work. Amwell is losing customers and revenue is down about one-fifth each year. The company promised it would make money by late 2026, but that has not happened yet, and the whole future depends on whether that promise comes true or whether customers keep leaving for cheaper or easier options.

Why
01
AI pressure: None apparent. No AI lab directly displaces Amwell yet; management just plugs third-party AI tools into its platform as a feature, not a defense. Could AI do the core job? Yes, likely.
02
Bigger players: Zoom and Epic Systems. Zoom now leads telehealth video by share, and Epic bundles its own telehealth into the health record where doctors already work. Could a giant copy it? Yes, easily.
03
What protects it. Government and payer contracts like DHA/Leidos and Elevance lock Amwell into workflows that are slow and costly to rip out.
What would change this call
Amwell reports Q4 2026 operating cash flow figure. Shows whether the survival plan is on track or the company is running out of runway.
Elevance Health or DHA/Leidos contract renewal or termination news. Tests whether Amwell's core enterprise logos are staying or leaving for rivals.
Amwell subscription revenue churn rate in quarterly filings after Q1 2026. Indicates if customer losses to Zoom or Epic are accelerating or stabilizing.
Key numbers
  • FY2025 revenue $249.3M, down from $254.4M (2025-12-31)
  • Headcount cut 43% in two years, to 562 (2025-12-31)
  • Stock down ~98% since 2020 IPO (2026-07-22)
Named risks
  • Revenue decline of ~18-20% YoY continuing into 2026 guidance. Severity: high
  • Subscription churn of -23% YoY threatens recurring-revenue narrative. Severity: high
  • Entire equity thesis hinges on unproven Q4 2026 operating cash flow breakeven. Severity: high
  • Headcount down ~43% in two years signals ongoing distress and execution risk. Severity: medium
  • Stock down ~98% since IPO with governance uncertainty from co-founder board exit. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Zoomgaining onRanked #1 U.S. telehealth vendor by share vs Amwell's 13.7% as of Nov 2025
Teladoc Healthlosing toHolds roughly 25% telehealth market share in 2024, far exceeding Amwell's share
Epic Systemslosing toBundles native telehealth directly into the EHR that Amwell integrates with, per 2026 brief
MDLIVE (Cigna/Evernorth)contestingPayer-integrated telehealth competitor overlapping Amwell's payer channel as of 2025
Doxy.megaining onLow-cost browser-based tool gaining share among small practices per 2025 market data
Questions people ask
Is Amwell profitable in 2026?
No. Amwell posted a $95.7M net loss for FY2025 (vs $212.6M in 2024) and guided Q1 2026 revenue down ~18% YoY to $54.9M. Management targets positive operating cash flow only by Q4 2026, a goal not yet achieved as of mid-2026.
Could AI replace Amwell?
Partially. AI-driven triage and generic video tools already erode Amwell's basic video-visit business, but Amwell hosts third-party AI as 'open architecture' rather than owning proprietary AI, and its regulated contracts (DHA, Elevance) offer some AI-resistant lock-in as of May 2026.
Who is Amwell's biggest competitor?
Zoom ranked #1 by U.S. telehealth vendor market share as of November 2025, with Amwell #2 at 13.7%. Teladoc Health holds roughly 25% telehealth market share in 2024, making it the larger established incumbent Amwell competes against.
Who owns Amwell?
Amwell (NYSE: AMWL) is publicly traded with no parent company. It IPO'd on September 17, 2020; founders Ido and Roy Schoenberg historically held Class B shares with 51% voting power, and Google/Alphabet took a concurrent roughly $100 million stake at IPO.
Is Amwell's revenue growing or shrinking?
Shrinking. FY2025 total revenue was $249.3M, down from $254.4M in 2024, and Q1 2026 revenue fell ~18% YoY to $54.9M. FY2026 guidance projects further decline to $195M to $205M in total revenue, per the May 6, 2026 earnings call.
What happened to Amwell's stock price?
Amwell stock is down roughly 98% since its September 2020 IPO, as of May 2026. The company executed a 1-for-20 reverse stock split effective July 10-11, 2024, to maintain NYSE minimum-price compliance, and its market cap sat around $180-210M in July 2026.
Timeline
  • 2026-05-27Co-founder Executive Vice Chairman reportedly departs Amwell board, linked to Amazon health move
  • 2026-05-06Q1 2026 earnings call: FY2026 revenue guidance $195-205M, Q4 2026 cash flow breakeven target set
  • 2026-05-05Q1 2026 revenue reported at $54.9M, down ~18% YoY; subscription churn -23% YoY
  • 2026-02-17Amwell guides lower FY2026 revenue following FY2025 results
  • 2026-02-11FY2025 results: revenue $249.3M, net loss narrows to $95.7M from $212.6M in 2024
  • 2025-01-31Amwell divests psychiatric care business (APC) to Avel eCare for $21M
  • 2024-07-111-for-20 reverse stock split takes effect to maintain NYSE listing compliance
  • 2024-02-14Amwell reports FY2023 net loss of $679M driven by goodwill impairments
  • 2023-10-18Defense Health Agency selects Amwell and Leidos for task order worth up to $180-258M
  • 2020-09-17Amwell IPOs on NYSE, raising roughly $618-742M with Google taking ~$100M stake
Revision history
22 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
23andMeAngelalign TechnologySharecare
More in Medical technology and health companies →
Sources